Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Chidamide||CS055|HBI-8000|Epidaza||HDAC Inhibitor 38||Chidamide (CS055) is an HDAC inhibitor, which may lead to increased apoptosis and decreased proliferation of tumor cells (PMID: 25384499).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||peripheral T-cell lymphoma||not applicable||Chidamide||Phase II||Actionable||In a Phase II trial, Chidamide (CS055) demonstrated a 28% (22/79) overall response rate in refractory peripheral T-cell lymphoma patients (PMID: 26105599).||26105599|
|Unknown unknown||pancreatic cancer||not applicable||Chidamide||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Chidamide (CS055) inhibited growth of a human pancreatic cancer cell line in culture and inhibited tumor growth in xenograft models (PMID: 25384499).||25384499|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|